Conformer- and alignment-independent model for predicting structurally diverse competitive CYP2C9 inhibitors

被引:50
作者
Afzelius, L [1 ]
Zamora, I
Masimirembwa, CM
Karlén, A
Andersson, TB
Mecucci, S
Baroni, M
Cruciani, G
机构
[1] AstraZeneca R&D, DMPK, S-43183 Molndal, Sweden
[2] Uppsala Univ, Dept Organ Pharmaceut Chem, S-75123 Uppsala, Sweden
[3] Lead Mol Design, Barcelona 08190, Spain
[4] Univ Perugia, Lab Chemometr, I-06100 Perugia, Italy
关键词
D O I
10.1021/jm030972s
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
A conformer- and alignment-independent three-dimensional structure-activity relationship (3D-QSAR) model has been derived that is based on flexible molecular interaction fields calculated in GRID and the subsequent description of these fields by use of alignment-independent descriptors derived in ALMOND. The training set consisted of 22 diverse and flexible competitive inhibitors of the drug-metabolizing enzyme CYP2C9 and generated a model with r(2) of 0.81 and q(2) of 0.62. The predicitive capacity of the model was externally evaluated with a test set of 12 competitive inhibitors and 11 out of 12 were predicted within 0.5 log unit. The most relevant points of interaction in the model correlated well to the amino acids involved in CYP2C9-substrate/inhibitor binding in the active site of a CYP2C9 homology model, further validating the mechanistic sense of our model.. This approach offers the possibility to derive predictive 3D-QSAR models without the need for an alignment rule for chemically diverse ligands and in the absence of target protein crystal structure information.
引用
收藏
页码:907 / 914
页数:8
相关论文
共 23 条
  • [1] Discriminant and quantitative PLS analysis of competitive CYP2C9 inhibitors versus non-inhibitors using alignment independent GRIND descriptors
    Afzelius, L
    Masimirembwa, CM
    Karlén, A
    Andersson, TB
    Zamora, I
    [J]. JOURNAL OF COMPUTER-AIDED MOLECULAR DESIGN, 2002, 16 (07) : 443 - 458
  • [2] Competitive CYP2C9 inhibitors:: Enzyme inhibition studies, protein homology modeling, and three-dimensional quantitative structure-activity relationship analysis
    Afzelius, L
    Zamora, I
    Ridderström, M
    Andersson, TB
    Karlén, A
    Masimirembwa, CM
    [J]. MOLECULAR PHARMACOLOGY, 2001, 59 (04) : 909 - 919
  • [3] BARDSLEY WG, 1993, MODERN TRENDS IN BIOTHERMOKINETICS, P455
  • [4] A novel approach to predicting P450 mediated drug metabolism. CYP2D6 catalyzed N-dealkylation reactions and qualitative metabolite predictions using a combined protein and pharmacophore model for CYP2D6
    de Groot, MJ
    Ackland, MJ
    Horne, VA
    Alex, AA
    Jones, BC
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 1999, 42 (20) : 4062 - 4070
  • [5] Novel approach to predicting P450-mediated drug metabolism: Development of a combined protein and pharmacophore model for CYP2D6
    de Groot, MJ
    Ackland, MJ
    Horne, VA
    Alex, AA
    Jones, BC
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 1999, 42 (09) : 1515 - 1524
  • [6] Development of a combined protein and pharmacophore model for cytochrome P4502C9
    de Groot, MJ
    Alex, AA
    Jones, BC
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 2002, 45 (10) : 1983 - 1993
  • [7] Pharmacophore modeling of cytochromes P450
    de Groot, MJ
    Ekins, S
    [J]. ADVANCED DRUG DELIVERY REVIEWS, 2002, 54 (03) : 367 - 383
  • [8] Modeling the active sites of cytochrome P450s and glutathione S-transferases, two of the most important biotransformation enzymes
    DeGroot, MJ
    Vermeulen, NPE
    [J]. DRUG METABOLISM REVIEWS, 1997, 29 (03) : 747 - 799
  • [9] Ekins S, 2000, DRUG METAB DISPOS, V28, P994
  • [10] Ekins S, 2001, DRUG METAB DISPOS, V29, P936